Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2017 /
Combination chemotherapy for multiple myeloma

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.17
Views: 2149
Rating:

Dr Muzaffar Qazilbash - MD Anderson Cancer Center, Houston, USA

Dr Qazilbash speaks with ecancer at the ASH 2017 annual meeting about the outcomes of a phase III trial of melphalan with busulfan as induction therapy for multiple myeloma patients.

He outlines the current schedule of induction therapy, and improvements in response duration and progression-free survival seen in the experimental arm.

Dr Qazilbash also describes the increased toxicity as reversible, and with no particularly vulnerable patient group, recommending the combination for further evaluation in larger trials.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation